Ginkgo Bioworks Holdings, Inc. (DNA)Healthcare | Biotechnology | Boston, United States | NYSE
9.05 USD
-0.04
(-0.440%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 6:15 a.m. EDT
The investment case for Ginkgo Bioworks is currently broken by a catastrophic multi-year decline. The stock has lost 97.5% of its value over the last four years, with every single year showing negative returns. This is not a temporary correction; it is a structural implosion where the market has repeatedly rejected the company's value proposition, culminating in a divestiture of its biosecurity unit and a pivot to autonomous labs. Fundamentally, the picture is dire: revenue is contracting by nearly half (-49%), the company is burning massive cash with negative operating cash flow, and it carries more debt than cash on hand. The balance sheet is fragile, and the return on equity is deeply negative. There is no dividend to provide income, and the lack of growth makes any valuation multiple unjustifiable. While insiders recently sold shares at lower prices, this confirms management's belief that the current share price does not reflect the company's true worth. The options market agrees, with traders aggressively buying puts to protect against further drops. Until the autonomous lab strategy proves it can generate significant revenue and profitability without further capital dilution, this remains a high-risk speculative vehicle with no margin of safety. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.121258 |
| AutoETS | 0.125492 |
| AutoTheta | 0.186141 |
| AutoARIMA | 0.220919 |
| MSTL_115 | 0.269663 |
| MSTL_42 | 0.321010 |
| MSTL_42_115 | 0.359308 |
Forecast horizon: 60 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 2.08 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.157 |
| Excess Kurtosis | -1.12 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 92.677 |
| Revenue per Share | 2.666 |
| Market Cap | 591,186,688 |
| Forward P/E | -2.82 |
| Beta | 1.78 |
| Profit Margins | -201.05% |
| Website | https://www.ginkgo.bio |
As of July 11, 2026, 6:15 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Put open interest significantly exceeds call open interest across nearly all expirations, with heavy concentration in strikes below the current price (e.g., $5, $6, $7, $8). While there is some volume in deep out-of-the-money calls ($16-$20 strikes), the dominant theme is hedging against further declines, suggesting a consensus view of continued weakness or a 'wait and see' approach to avoid buying the dip.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.085513055 |
| Address1 | 27 Drydock Avenue |
| Address2 | 8th Floor |
| All Time High | 634.56 |
| All Time Low | 5.0 |
| Ask | 0.0 |
| Ask Size | 300 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 1,341,920 |
| Average Daily Volume3 Month | 1,289,731 |
| Average Volume | 1,289,731 |
| Average Volume10Days | 1,341,920 |
| Beta | 1.778 |
| Bid | 0.0 |
| Bid Size | 300 |
| Board Risk | 10 |
| Book Value | 7.187 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 9.05 |
| Current Ratio | 5.151 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 9.325 |
| Day Low | 8.86 |
| Debt To Equity | 92.677 |
| Display Name | Ginkgo Bioworks |
| Earnings Call Timestamp End | 1,778,185,800 |
| Earnings Call Timestamp Start | 1,778,185,800 |
| Earnings Timestamp | 1,778,184,000 |
| Earnings Timestamp End | 1,786,046,400 |
| Earnings Timestamp Start | 1,786,046,400 |
| Ebitda | -262,492,992 |
| Ebitda Margins | -1.73378 |
| Enterprise To Ebitda | -2.394 |
| Enterprise To Revenue | 4.151 |
| Enterprise Value | 628,430,656 |
| Eps Current Year | -3.42 |
| Eps Forward | -3.21 |
| Eps Trailing Twelve Months | -5.36 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 8.9066 |
| Fifty Day Average Change | 0.14340019 |
| Fifty Day Average Change Percent | 0.016100442 |
| Fifty Two Week Change Percent | -8.551306 |
| Fifty Two Week High | 17.58 |
| Fifty Two Week High Change | -8.53 |
| Fifty Two Week High Change Percent | -0.48521045 |
| Fifty Two Week Low | 5.37 |
| Fifty Two Week Low Change | 3.6800003 |
| Fifty Two Week Low Change Percent | 0.6852887 |
| Fifty Two Week Range | 5.37 - 17.58 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,618,839,000,000 |
| Float Shares | 47,851,496 |
| Forward Eps | -3.21 |
| Forward P E | -2.8193147 |
| Free Cashflow | -77,930,000 |
| Full Exchange Name | NYSE |
| Full Time Employees | 485 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.69629997 |
| Gross Profits | 105,419,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04599 |
| Held Percent Institutions | 0.68676 |
| Implied Shares Outstanding | 65,324,491 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,724,112,000 |
| Last Split Factor | 1:40 |
| Long Business Summary | Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. |
| Long Name | Ginkgo Bioworks Holdings, Inc. |
| Market | us_market |
| Market Cap | 591,186,688 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_130407341 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -305,512,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 593,799,622 |
| Number Of Analyst Opinions | 2 |
| Open | 8.87 |
| Operating Cashflow | -166,224,000 |
| Operating Margins | -3.66509 |
| Overall Risk | 10 |
| Payout Ratio | 0.0 |
| Phone | 877 422 5362 |
| Pre Market Change | -0.13850021 |
| Pre Market Change Percent | -1.5303891 |
| Pre Market Price | 8.9115 |
| Pre Market Time | 1,784,017,643 |
| Previous Close | 9.09 |
| Price Eps Current Year | -2.6461987 |
| Price Hint | 2 |
| Price To Book | 1.2592181 |
| Price To Sales Trailing12 Months | 3.9048254 |
| Profit Margins | -2.01054 |
| Quick Ratio | 4.947 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.04 |
| Regular Market Change Percent | -0.440044 |
| Regular Market Day High | 9.325 |
| Regular Market Day Low | 8.86 |
| Regular Market Day Range | 8.86 - 9.325 |
| Regular Market Open | 8.87 |
| Regular Market Previous Close | 9.09 |
| Regular Market Price | 9.05 |
| Regular Market Time | 1,783,972,802 |
| Regular Market Volume | 654,970 |
| Return On Assets | -0.16159001 |
| Return On Equity | -0.56027 |
| Revenue Growth | -0.491 |
| Revenue Per Share | 2.666 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 53,361,141 |
| Shares Percent Shares Out | 0.079 |
| Shares Short | 5,160,266 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 4,562,024 |
| Short Name | Ginkgo Bioworks Holdings, Inc. |
| Short Percent Of Float | 0.1 |
| Short Ratio | 3.72 |
| Source Interval | 15 |
| State | MA |
| Symbol | DNA |
| Target High Price | 12.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 8.5 |
| Target Median Price | 8.5 |
| Total Cash | 373,456,000 |
| Total Cash Per Share | 5.717 |
| Total Debt | 410,700,000 |
| Total Revenue | 151,399,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.36 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.2876 |
| Two Hundred Day Average Change | -0.23759937 |
| Two Hundred Day Average Change Percent | -0.02558243 |
| Type Disp | Equity |
| Volume | 654,970 |
| Website | https://www.ginkgo.bio |
| Zip | 2,210 |